59 results
8-K
EX-99.2
AXLA
Axcella Health Inc.
29 Sep 22
Regulation FD Disclosure
9:15am
or at all due to patient or principal investigator recruitment or availability challenges, cli nic al trial site shutdowns or other interruptions … Decreases Hepatocyte Damage and Promotes Immune Recruitment AXA1125 Decreases Hepatocyte Damage and Immune Cell Recruitment and Decreases
8-K
AXLA
Axcella Health Inc.
29 Aug 23
Axcella Granted Patent for Long COVID Fatigue Treatment
8:17am
and complete its ongoing or planned clinical studies and clinical trials in a timely manner or at all due to patient or principal investigator recruitment
8-K
EX-99.1
AXLA
Axcella Health Inc.
7 Dec 21
Departure of Directors or Certain Officers
6:15am
or planned clinical studies and clinical trials in a timely manner or at all due to patient or principal investigator recruitment or availability
8-K
EX-99.1
AXLA
Axcella Health Inc.
7 Feb 22
Axcella Therapeutics Announces Appointment of New Chief Financial Officer
4:00pm
manner or at all due to patient or principal investigator recruitment or availability challenges, clinical trial site shutdowns or other interruptions
8-K
EX-99.1
AXLA
Axcella Health Inc.
29 Aug 23
Axcella Granted Patent for Long COVID Fatigue Treatment
8:17am
its ongoing or planned clinical studies and clinical trials in a timely manner or at all due to patient or principal investigator recruitment
8-K
EX-99.1
d9ewwfz1qvg1wcp1u
3 Mar 21
Axcella Announces Alison D. Schecter, M.D., as President of R&D
5:26pm
8-K
EX-99.1
wsiz2m3ok2x
26 May 22
Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio
8:12am
8-K
EX-99.1
6v42n9f3q8yo152
3 Aug 23
Axcella Reports Second Quarter Financial Results and Provides Business Update
8:04am
8-K
EX-99.1
s2l mvojfqj
5 May 22
Axcella Reports First Quarter Financial Results and Provides Business Update
7:41am
8-K
EX-99.1
o0y92l2krs7vzh0
12 Aug 22
Axcella Reports Second Quarter Financial Results and Provides Business Update
8:11am
8-K
obt4 0sv53j
29 Sep 22
Regulation FD Disclosure
9:15am
8-K
EX-99.1
t1wgyeyehi1rg
4 May 23
Axcella Reports First Quarter Financial Results and Provides Business Update
4:33pm
8-K
EX-99.1
f8tgv0eal10
15 Dec 22
Axcella Announces Program Reprioritization and Corporate Restructuring Move Positions Company to Best Focus on Long COVID Program
7:00am
8-K
EX-99.1
g71xj4 obr7zcbycl
29 Sep 22
Regulation FD Disclosure
9:15am
8-K
EX-99.1
5g5rdf
13 Oct 22
Entry into a Material Definitive Agreement
8:15am
8-K
yjmb1yg uqlde4
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
EX-99.1
2fa7lfsyp8q
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
EX-99.1
ulopkp2a001m
6 May 21
Axcella Reports First Quarter Financial Results and Provides Business Update
7:51am
8-K
EX-99.1
l7las
10 Nov 21
Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials
8:08am
8-K
EX-99.1
efi4qt yx48
11 May 20
Axcella Reports First Quarter Financial Results and Provides Business Update
8:13am